Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma

NCT04652492 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Tislelizumab in combination with cTACE

Sponsor

Zhongda Hospital